Work

Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct147

Authors: Andrew Garton, Vinu Menon, Hang Quach, Amit Khot, Brad Augustson, Hanlon Sia, David Levitz, Eben Lichtman, Michaela Liedtke, Camille Martinet, Beata Holkova, Lida Pacaud, Sunitha GN, Maria Pihlgren, Mario Perro, Cyril Konto

Institutions: St Vincent's Hospital Melbourne, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Sir Charles Gairdner Hospital, Linear Clinical Research, Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Stanford Medicine, Stanford University, Glenmark Pharmaceuticals (India)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821970

Cites:

Cited by: 1

Related to: 10